Seminars in Oncology
Volume 36, Issue 3 , Pages 250-257 , June 2009

The Unique Characteristics of Ovarian Carcinogenesis in the Adolescent and Young Adult Population

  • Darlene G. Gibbon

      Affiliations

    • Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, The Cancer Institute of New Jersey, New Brunswick, NJ
    • Corresponding Author InformationAddress correspondence to Darlene G. Gibbon, MD, The Cancer Institute of New Jersey, 195 Little Albany St, New Brunswick, NJ 08901
    • ,
  • Concepcion Diaz-Arrastia

      Affiliations

    • Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Texas Medical Branch–Galveston, Galveston, TX

References 

  1. Bleyer A, Viny A, Barr R. Cancer in 15- to 29-year olds by primary site. Oncologist. 2006;11:590–601
  2. Wu X, Grove FD, McLaughlin CC, Jemal A, Martin A, Chen VW. Cancer incidence patterns among adolescents and young adults in the United States. Cancer Causes Control. 2005;16:309–320
  3. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology and pathology. Endocrine Rev. 2001;22:255–288
  4. Osterholzer HO, Streibel EJ, Nicosia SV. Growth effects of protein hormones on cultured rabbit ovarian surface epithelial cells. Biol Reprod. 1985;33:247–258
  5. Ackerman RC, Murdoch WJ. Prostaglandin-induced apoptosis of ovarian surface epithelial cells. Prostaglandins. 1993;45:475–485
  6. Murdoch WJ. Programmed cell death in preovulatory ovine follicles. Biol Reprod. 1995;53:8–12
  7. Auersperg N, Woo MM, Gilks CB. The origin of ovarian carcinomas: a developmental view. Gynecol Oncol. 2008;110:452–454
  8. Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev. 2005;14:98–107
  9. Godwin AK, Perez RP, Johnson SW, Hamaguchi K, Hamilton TC. Growth regulation of ovarian cancer. Hematol Oncol Clin North Am. 1992;6:829–841
  10. Daly M, Obrams GI. Epidemiology and risk assessment for ovarian cancer. Semin Oncol. 1998;25:255–264
  11. Casagrande JT, Louie EW, Pike MC, Roy S, Russ RK, Henderson BE. Incessant ovulation and ovarian cancer. Lancet. 1979;2:170–173
  12. Fathalla MF. Incessant ovulation-factor in ovarian neoplasia. Lancet. 1971;2:163
  13. Bell DA, Scully RE. Early de novo ovarian carcinoma (A study of fourteen cases). Cancer. 1994;73:1859–1864
  14. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II (Inferences regarding pathogenesis). J Natl Cancer Inst. 1983;71:717–721
  15. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst. 1999;91:1459–1467
  16. Brinton LA, Sakoda LC, Sherman ME, Frederiksen K, Kjaer SK, Graubard BI, et al. Relationship of benign gynecologic diseases to subsequent risk of ovarian and uterine tumors. Cancer Epidemiol Biomarkers Prev. 2005;14:2929–2935
  17. Beral V, Doll R, Hermon C, Peto R, Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371:303–314
  18. Casagrande JT, Pike MC, Henderson BE. Oral contraceptives and ovarian cancer. N Engl J Med. 1983;308:843–844
  19. Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, et al. Combined oral contraceptive use and epithelial ovarian cancer risk: time-related effects. Epidemiology. 2008;19:237–243
  20. Rutherford T, Brown WD, Sapi E, Aschkenazi S, Munoz A, Mor G. Absence of estrogen receptor-beta expression in metastatic ovarian cancer. Obstet Gynecol. 2000;96:417–421
  21. Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carnney ME, Terada KY, et al. Genetic polymorphisms in the estrogen receptor beta (ESR2) gene and the risk of epithelial ovarian carcinoma. Cancer Causes Control. 2009;20:47–55
  22. Cnattingius S, Eloranta S, Adami HO, Axelsson O, Dickman PW, Chung-cheng H, et al. Placental weight and risk of invasive epithelial ovarian cancer with an early age of onset. Cancer Epidemiol Biomarkers Prev. 2008;17:2344–2349
  23. Mucci LA, Dickman PW, Lambe M, Adami HO, Trichopoulos D, Riman T, et al. Gestational age and fetal growth in relation to maternal ovarian cancer risk in a Swedish cohort. Cancer Epidemiol Biomarkers Prev. 2007;16:1828–1832
  24. Mucci LA, Lagiou P, Tamimi RM, Hsieh CC, Adami HO, Trichopoulos D. Pregnancy estriol, estradiol, progesterone and prolactin in relation to birth weight and other birth size variables (Unites States). Cancer Causes Control. 2003;14:311–318
  25. Kaijser M, Granath F, Jacobsen G, Cnattingius S, Ekbom A. Maternal pregnancy estriol levels in relation to anamnestic and fetal anthropometric data. Epidemiology. 2000;11:315–319
  26. Mucci LA, Dickman PW, Lambe M, Adami HO, Trichopoulos D, Riman T, et al. Gestational age and fetal growth in relation to maternal ovarian cancer risk in a Swedish cohort. Cancer Epidemiol Biomarkers Prev. 2007;16:1828–1832
  27. Baik I, Lambe M, Liu Q, Cnattingius S, Mucci LA, Riman T, et al. Gender of offspring and maternal risk of invasive epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:2314–2320
  28. Fisher DA. The unique endocrine milieu of the fetus. J Clin Invest. 1986;78:603–611
  29. Munstedt K, Steen J, Knauf AG, Buch T, von Georgi R, Franke FE, et al. Steroid hormone receptors and long term survival in invasive ovarian cancer. Cancer. 2000;89:1783–1791
  30. Coppola D, Saunders B, Fu L, Mao W, Nicosia SV. The insulin-like growth factor I receptor induces transformation and tumorigenicity of ovarian mesothelial cells and down-regulates their Fas-receptor expression. Cancer Res. 1999;59:3264–3270
  31. Karasik A, Menczer J, Pariente C, Kanety H. Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab. 1994;78:271–276
  32. Monaghan JM, Godber IM, Lawson N, Kaur M, Wark G, Teale D, et al. Longitudinal changes of insulin-like growth factors and their binding proteins throughout normal pregnancy. Ann Clin Biochem. 2005;41:220–226
  33. Clapp JF, Schmidt S, Paranjape A, Lopez B. maternal insulin-like growth factor-I levels (IGF-I) reflect placental mass and neonatal fat mass. Am J Obstet Gynecol. 2004;190:730–736
  34. Laviola L, Perrini S, Belsanti G, Natalicchio A, Montrone C, Leonardini A, et al. Intrauterine growth restriction in humans is associated with abnormalities in placental insulin-like growth factor signaling. Endocrinology. 2005;146:1498–1505
  35. Rinaladi S, Dossus L, Lukanova A, et al. Endogenous androgens and risk of epithelial ovarian cancer: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Epidemiol Biomarkers Prev. 2007;16:23–29
  36. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst. 1998;90:1774–1786
  37. Domanska K, Malander S, Masback A, Nilbert M. Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40. Int J Gynecol Cancer. 2007;17:789–793
  38. Stratton JF, Thompson D, Bobrow L, Dalal N, Gore M, Bishop DT, et al. The genetic epidemiology of early-onset epithelial ovarian cancer: a population-based study. Am J Hum Genet. 1999;65:1725–1732
  39. Tonin PN, Maugard , Perret C, Mes-Masson AM, Provencher DM. A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families. Familial Cancer. 2007;6:491–497
  40. Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007;25:3985–3990
  41. Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006;100:58–64
  42. Saleemuddin A, Folkins AK, Garrett L, Garber J, Muto MG, Crum CP, et al. Risk factors for a serous cancer precursor (“p53 signature”) in women with inherited BRCA mutations. Gynecol Oncol. 2008;111:226–232
  43. Cass I, Holschneider C, Datta N, Barbuto D, Walts AE, Karlan BY. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?. Obstet Gynecol. 2007;106:1327–1334
  44. Kindelberger D, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intra-epithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31:161–169
  45. SGO Committee Statement. Society of Gynecologic Oncologist Clinical Practice Committee. Statement on Prophylactic Salpingo-oophorectomy. Gynecol Oncol. 2005;98:179–181
  46. Classification and staging of malignant tumors in the female pelvis. Acta Obstet Gynecol Scand. 1971;50:1–7
  47. Shimizu Y, Kamoi S, Amada S, Hasumi K, Akiyama F, Silverberg SG. Toward the development of a universal grading system for ovarian epithelial carcinoma testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer. 1998;82:893–901
  48. Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004;28:496–504
  49. Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006;108:361–369
  50. Seidman JD, Kurman RJ. Subclassification of serous borderline tumors of the ovary into benign and malignant types (A clinicopathologic study of 65 advanced stage cases). Am J Surg Pathol. 1996;20:1331–1345
  51. Burks RT, Sherman ME, Kurman RJ, et al. Micropapillary serous carcinoma of the ovary: a distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol. 1996;20:1319–1330
  52. Eichhorn JH, Bell DA, Young RH, Scully RE. Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns. Am J Surg Pathol. 1999;23:397–409
  53. Deaver MT, Gershenson DM, Tortolero-Luna G, Malpica A, Lu KH, Silva EG. Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases. Am J Surg Pathol. 2002;26:1129–1141
  54. Silva EG, Kurman RJ, Russell P, Scully RE. Symposium: ovarian tumors of borderline malignancy. Int J Gynecol Pathol. 1996;15:281–302
  55. Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih IeM. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol. 2008;198:351–356
  56. Singer G, Stohr R, Cope L, Dehari R, Harmann A, Cao DF, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis (A mutational analysis with immunohistochemical correlation). Am J Surg Pathol. 2005;29:218–224
  57. Sieben NL, Macropoulos P, Roemen GM, Kolkman-Uljee SM, Jan Fleuren G, Houmadi R, et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol. 2004;202:336–340
  58. Singer G, Oldt R, Cohen Y, Wang BG, Sidransky D, Kurman RJ, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003;95:484–486
  59. Shih IM, Kurman RJ. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res. 2005;11:7273–7279
  60. Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, et al. Expression profiling of serous low malignant potential, low-grade and high-grade tumors of the ovary. Cancer Res. 2005;65:10602–10612
  61. Chan JK, Urban R, Cheung MK, Osann K, Husain A, Teng NN, et al. Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer. 2006;95:1314–1320
  62. Chan JK, Loizzi V, Lin YG, Osann K, Brewster WR, DiSaia PJ. Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important. Obstet Gynecol. 2003;102:156–161
  63. Thigpen T, Brady MF, Omura GA, Creasman WT, McGuire WP, Hoskins WJ, et al. Age as a prognostic factor in ovarian carcinoma (The Gynecologic Oncology Group experience). Cancer. 1993;71(Suppl):606–614
  64. Pectasides D, Fountzilas G, Aravantinos G, Bamias A, Kalofonos HP, Skarlos D, et al. Epithelial ovarian carcinoma in younger vs older women: is age an independent prognostic factor? (The Hellenic Oncology Cooperative Group experience). Int J Gynecol Cancer. 2007;17:1003–1010
  65. Plaxe SC, Braly PS, Freddo JL, McClay E, Kirmani S, Howell SB. Profiles of women age 30-39 and age less than 30 with epithelial ovarian cancer. Obstet Gynecol. 1993;81:651–654
  66. Duska LR, Chang Y, Flynn CE, Chen AH, Goodman A, Fuller AF, et al. Epithelial ovarian carcinoma in the reproductive age group. Cancer. 1999;85:2623–2629
  67. Massi D, Susini T, Savino L, Boddi V, Amunni G, Colafranceschi M. Epithelial ovarian tumors in the reproductive age group: age is not an independent prognostic factor. Cancer. 1996;77:1131–1136
  68. Bozas G, Dimopoulos MA, Kastritis E, Efstathios E, Koutsoukou V, Rodolakis A, et al. Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: a single institution experience. Oncology. 2006;70:265–272
  69. Zanetta G, Bonazzi C, Cantu MG, Binidagger S, Locatelli A, Bratina G, et al. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol. 2001;19:1015–1020
  70. Gotlieb WH, Flikker S, Davidson B, Korach Y, Kopolovic J, Ben-Baruch G. Borderline tumors of the ovary (Fertility treatment, conservative management, and pregnancy outcome). Cancer. 1998;82:141–146
  71. Schilder JM, Thompson AM, DePriest PD, Ueland FR, Cibull ML, Kryscio RJ, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol. 2002;87:1–7
  72. Morice P, Leblanc E, Rey A, Baron M, Querleu D, Blanchot J, et al. Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer: and SFOG (Societe Francaise d'Oncologie Gynecologique). Hum Reprod. 2005;20:1379–1385
  73. Ries LA, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975-2005. Bethesda, MD: National Cancer Institute; 2008;based on November 2006 SEER data submission, posted to the SEER website http://seer.cancer.gov/csr/1975_2008
  74. Almstrup K, Hoei-Hansen CE, Wirkner U, Blake J, Schwager C, Ansorge W, et al. Embryonic stem cell-like features of testicular carcinoma in situ revealed by genome-wide gene expression profiling. Cancer Res. 2004;64:4736–4743
  75. Hoei-Hansen CE, Kraggerud SM, Abeler VM, Kaern J, Rajpert-De Meyts E, et al. Ovarian dysgerminomas are characeterised by frequent KIT mutations and abundant expression of pluripotency markers. Mol Cancer. 2007;6:12
  76. Michala L, Goswami D, Creighton SM, Conway GS. Sawyer syndrome: presentation and outcomes. BJOG Int J Obstet Gynaecol. 2008;115:737–741
  77. Michala L, Palaia I, Sansone M, Calcagno M, Plotti F, Angioli R, et al. Laparoscopic fertility-sparing staging in unexpected early stage ovarian malignancies. Fertil Steril. June 12 2008;Epub ahead of print
  78. Colomer AT, Jiménez AM, Bover Barceló MI. Laparoscopic treatment and staging of early ovarian cancer. J Minim Invasive Gynecol. 2008;15:414–419
  79. Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, et al. Comparison of laparoscopy and laparotomy in surgical staging of early-stage ovarian and fallopian tubal cancer. Ann Surg Oncol. 2008;15:2012–2019
  80. Ghezzi F, Cromi A, Uccella S, Bergamini V, Tomera S, Franchi M, et al. Laparoscopy versus laparotomy for the surgical management of apparent early stage ovarian cancer. Gynecol Oncol. 2007;105:409–413
  81. Chan JK, Tewari KS, Waller S, Cheung MK, Shin JY, Osann K, et al. The influence of conservative surgical practices for malignant ovarian germ cell tumors. J Surg Oncol. 2008;98:111–116
  82. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Ovarian cancer. V.1. 2008;http://www.nccn.org/professionals/physician_gls/PDF/ovarian
  83. Tangir J, Zelterman D, Ma W, Schwartz PE. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstet Gynecol. 2003;101:251–257
  84. Kang H, Kim TJ, Kim WY, Choi CH, Lee JW, Kim BG, et al. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatinum (BEP) for patients with ovarian endodermal sinus tumor. Gynecol Oncol. 2008;111:106–110

PII: S0093-7754(09)00041-4

doi: 10.1053/j.seminoncol.2009.03.002

Seminars in Oncology
Volume 36, Issue 3 , Pages 250-257 , June 2009

Article Tools